Although most of the BACE inhibitors, such as verubecestat (MK-8931), were efficient in suppressing Aβ production in preclinical and clinical trials, they showed failure in phase III in mild to moderate AD patients due to toxicity or cognitive worsening compared to placebo-treated patients [4,26]. This evidence concerns the gene BACE1 and Alzheimer disease.